Iowa Medicaid GLP-1 Coverage 2026: Dual-Authority Regulatory Exclusion + Unified PA Form 470-0058 (Wegovy MACE + Zepbound OSA + Wegovy MASH) — PDL Comment Code 12 — Optum PBM

TL;DR

Iowa Medicaid — administered by Iowa HHS through three Iowa Health Link managed care organizations (Iowa Total Care/Centene, Wellpoint Iowa/Anthem, Molina Healthcare of Iowa), plus Fee-for-Service for aged-blind-disabled and dual-eligibles, plus the Iowa Health and Wellness Plan (IHAWP) expansion for adults 19–64 up to 133% FPL, all using the same statewide PDL with Optum (UnitedHealth Group subsidiary) as PBM — does NOT cover GLP-1 receptor agonists for adult chronic weight management. KFF’s January 2026 tracker classifies Iowa as NOT among the 13 covering states.

The exclusion operates at two parallel authorities simultaneously: the federal optional-exclusion at 42 U.S.C. § 1396r-8(d)(2)(A) (“Agents when used for anorexia, weight loss, or weight gain”) and the Iowa state regulatory exclusion at IAC 441-78.2(4)(b)(2) (“Drugs used for anorexia, weight gain, or weight loss”). Iowa Code §§ 249A.20A and 249A.24 provide the statutory authority for the PDL program and the DUR Commission respectively.

Iowa has preserved three FDA-label-restricted carve-outs delivered through a single unified PA pathway — the only state in the 31-state taxonomy to consolidate all three indication pathways into one form:

• Wegovy (semaglutide) for MACE risk reduction — adults ≥ 18, established CVD (coronary artery disease, cerebrovascular disease, peripheral arterial disease, heart failure, atrial fibrillation, valvular heart disease, congenital heart disease, cardiomyopathies, aortic disease, DVT, PE), BMI ≥ 27 kg/m² within 6 months, no T1DM/T2DM. More permissive than Oklahoma on age (≥ 18 vs. ≥ 45) and CVD breadth.
• Zepbound (tirzepatide) for moderate-to-severe OSA — BMI ≥ 30 kg/m², AHI ≥ 15 events/hour documented by polysomnography or at-home sleep study within prior 3 years, FDA-approved age for OSA.
• Wegovy (semaglutide) for noncirrhotic MASH — F2–F3 fibrosis confirmed by FibroScan VCTE 8–15 kPa, MRE 3.1–4.4 kPa, or liver biopsy NAS ≥ 4, no T1DM/T2DM, no cirrhosis, no significant alcohol consumption. Adopted approximately 5 months after the August 15, 2025 FDA approval.

All three are administered through Request for Prior Authorization form 470-0058 (rev 1/26), “Incretin Mimetics for Non-Diabetes Indications.” Fax to 1-800-574-2515. One form, one fax, three indications.

On the June 1, 2026 Iowa Medicaid PDL, Wegovy and Zepbound are listed as Preferred under the Endocrine Metabolic Agents class — but each carries comment code “12” = “PA Required. Weight loss indication not covered.” This dual-signaling is the most operationally explicit line-item treatment in the 31-state taxonomy of the distinction between PDL preferred status and indication-specific coverage status.

IHAWP operates under the same statewide PDL and PA criteria as Iowa Medicaid FFS — structurally complete parity; no separate expansion-population formulary or weight-management benefit.

SF 552 / HF 701 (2025–2026 Iowa legislature) is a review-and-report mandate only — it does NOT amend IAC 441-78.2(4)(b)(2) and does NOT mandate coverage. Status: “Referred to Health and Human Services” (June 16, 2025), no voting record. The HHS+DAS report due January 5, 2026 has not been verified as publicly published as of May 10, 2026.

The IAC 441-78.2(4)(b)(2) Regulatory Exclusion + Iowa Code §§ 249A.20A and 249A.24 Statutory Authority: The Dual-Authority Architecture

Iowa’s GLP-1 weight-management exclusion is anchored at two independent authority levels operating in parallel — a federal floor and a state regulatory ceiling — with Iowa statutory law providing the committee and commission infrastructure that maintains the PDL.

Federal Authority: 42 U.S.C. § 1396r-8(d)(2)(A)

The Medicaid statute gives every state the option to exclude weight-loss drugs from coverage. The verbatim federal text (verified via Cornell Law US Code mirror, law.cornell.edu/uscode/text/42/1396r-8, 2026-05-10):

“Subject to subsection (d)(3), the following drugs or classes of drugs, or their medical uses, may be excluded from coverage or otherwise restricted: (A) Agents when used for anorexia, weight loss, or weight gain.”

Iowa has fully invoked this exclusion authority for chronic weight management, placing it at the same structural position as Illinois (89 IAC § 140.441), Indiana (405 IAC 5-24-3(b)(1)), Kentucky (907 KAR 23:010 Section 5(2)(a)), Alabama (Ala. Admin. Code r. 560-X-16-.01(2)(b)), and Oklahoma (OAC 317:30-5-72.1(1)(D)).

State Regulatory Authority: IAC 441-78.2(4)(b)(2)

Iowa has operationalized the federal optional exclusion at the state administrative code level. The verbatim text of IAC 441-78.2(4)(b) (verified via legis.iowa.gov/docs/iac/chapter/441.78.pdf, effective IAC 10/15/25, 2026-05-10):

“b. Payment is not made for:
 (1) Drugs whose prescribed use is not for a medically accepted indication as defined by Section 1927(k)(6) of the Social Security Act.
 (2) Drugs used for anorexia, weight gain, or weight loss.
 (3) Drugs used for cosmetic purposes or hair growth.”

IAC 441-78.2(4)(b)(2) — “Drugs used for anorexia, weight gain, or weight loss” — is the canonical Iowa state regulatory exclusion. It mirrors the federal optional-exclusion language at 42 U.S.C. § 1396r-8(d)(2)(A) almost verbatim. The exclusion does NOT contain a categorical override clause for FDA-label cardiometabolic indications — the three carve-outs are operationalized through the separate Incretin Mimetics for Non-Diabetes Indications PA Criteria document, which explicitly cross-references IAC 441-78.2(4).

The parent rule, IAC 441-78.2(4)(a), confirms that prior authorization is required for all non-PDL drugs: “Prior authorization is required as specified in the preferred drug list published by the department pursuant to Iowa Code section 249A.20A.”

Statutory Authority: Iowa Code §§ 249A.20A and 249A.24

Iowa Medicaid’s PDL and DUR infrastructure rests on two distinct statutory committees (verified via legis.iowa.gov/docs/code/249A.pdf, Iowa Code 2026 edition, 2026-05-10):

Iowa Code § 249A.20A (Preferred Drug List Program) created the Pharmaceutical and Therapeutics (P&T) Committee by gubernatorial appointment, two-year terms, to develop and review the PDL:

“249A.20A Preferred drug list program. 1. The department shall establish and implement a preferred drug list program under the medical assistance program. ... 2. a. A medical assistance pharmaceutical and therapeutics committee shall be established within the department by July 1, 2003, for the purpose of developing and providing ongoing review of the preferred drug list. ... 3. b. The committee shall develop the preferred drug list by considering each drug’s clinically meaningful therapeutic advantages in terms of safety, effectiveness, and clinical outcome. c. The committee shall use evidence-based research methods in selecting the drugs to be included on the preferred drug list.”

Iowa Code § 249A.24 created a separate Iowa Medical Assistance Drug Utilization Review (DUR) Commission:

“249A.24 Iowa medical assistance drug utilization review commission — created. 1. An Iowa medical assistance drug utilization review commission is created within the department. The commission membership, duties, and related provisions shall comply with 42 C.F.R. pt. 456, subpt. K. ... The strategies to be considered for recommendation by the commission shall include at a minimum all of the following: a. Development of a preferred drug formulary pursuant to 42 U.S.C. § 1396r-8. ... j. Expansion of prior authorization for prescription drugs and pharmaceutical case management under the medical assistance program.”

The P&T Committee (§ 249A.20A) recommends PDL placement; the DUR Commission (§ 249A.24) recommends cost-saving strategies including PA expansion. P&T Committee meeting minutes and DUR Commission minutes for 2024–2026 were not accessible to this brief — navigation paths at iowamedicaidpdl.com/committee/ return 404 errors.

The Anti-Diabetics, Non-Insulin Agents PA Criteria (June 1, 2026 version, page 4 of 82) closes the exclusion loop at the diabetes-track level with the most operationally direct sentence in the Iowa Medicaid PA infrastructure:

“Requests for weight loss, which is not a covered diagnosis of use, will be denied.”

This sentence applies to all anti-diabetic GLP-1 receptor agonists (Mounjaro, Ozempic, Trulicity, Victoza, Rybelsus, Exenatide). A T2DM-eligible patient submitting Mounjaro for off-label weight management will receive a hard denial at the PA criteria level.

PDL Comment Code 12: “PA Required. Weight Loss Indication Not Covered” — The Most Operationally Explicit PDL Signaling in the 31-State Series

Iowa Medicaid’s June 1, 2026 Preferred Drug List (PDF, 1.5MB, document control number RT14773, generated 4/24/2026 11:15:53 AM, hosted at iowamedicaidpdl.com/content/dam/ffs-medicaid/ia/ia-pdl-effective-06012026.pdf, 108 pages) carries a comment-code legend that is unique in the 31-state series. The verbatim PDL legend:

“P, N, R, or NR:
P = Preferred
N = Non-Preferred
R = Recommended
NR = Non-Recommended

Key to Color Highlights:
Blue - Changes in PDL Status/PA Criteria
Pink - New Drugs
Blue Underline - Click hyperlink for PA Form
Hover to the left of Comment Number for comment text”

The verbatim comment-code table:

“Comment Num | Comment
11           | PA Required
12           | PA Required. Weight loss indication not covered”

The verbatim PDL entries for Wegovy and Zepbound under the “Endocrine Metabolic Agents” therapeutic class:

“Endocrine Metabolic Agents
B           N    Rezdiffra
B    12   P    Wegovy    [PA Form: incretin-mimetics-non-diabetes-pa-npi-0126.pdf]
B    12   P    Zepbound  [PA Form: incretin-mimetics-non-diabetes-pa-npi-0126.pdf]
B           N    Crenessity”

The structural significance of this dual-signaling pattern is unique in the 31-state taxonomy. Most states in the categorical-exclusion cluster handle Wegovy and Zepbound one of three ways: (a) omit them from the PDL entirely (Texas, Florida, Georgia — operationally treating absence as the coverage-restriction signal); (b) list them as Non-Preferred with conditions (Kentucky, Alabama); or (c) list them in a separate non-weight-management drug class without a weight-loss-exclusion footnote (Ohio’s Metabolic Modifiers class). Iowa is the only state in the 31-state taxonomy that simultaneously marks Wegovy and Zepbound as Preferred AND attaches an explicit weight-loss-exclusion footnote (comment code 12) at the PDL line-item level.

What “Preferred with comment code 12” means operationally:

• For prescribers: The Preferred designation means “if the patient qualifies under the MACE/OSA/MASH carve-out, this is the on-formulary product — use form 470-0058.” The comment-12 footnote means “weight-loss indication will deny.”
• For pharmacy systems: A Wegovy or Zepbound claim submitted with a weight-management ICD-10 code (E66.9, E66.01, etc.) will reject at the point-of-sale because the weight-loss indication is not covered. The appropriate claim pathway for MACE/OSA/MASH patients requires a PA approval number before the claim is adjudicated.
• The YMYL trap to avoid: Iowa-resident patients or prescribers who see “Wegovy: Preferred” on the PDL and submit a chronic-weight-management PA will receive a denial. The PDL-preferred status is an indication-scoped procurement decision, not a blanket coverage approval.

The diabetic-class PDL entries carry comment code “11” (PA Required, without the weight-loss exclusion footnote) — Mounjaro, Trulicity, Victoza, Ozempic, Rybelsus, and Exenatide are Preferred for T2DM; Bydureon BCise and generic liraglutide are Non-Preferred. Brand Saxenda is not listed (because the obesity-indication formulation of liraglutide is excluded). Foundayo (orforglipron), Imcivree (setmelanotide), Qsymia, Contrave, phentermine HCl (Adipex-P), and orlistat are not listed anywhere in the June 1, 2026 PDL — operationally excluded by primary-source absence.

The Unified PA Form 470-0058: “Incretin Mimetics for Non-Diabetes Indications” — One Form Covers All Three Carve-Outs

Iowa’s unified PA approach is structurally distinctive in the 31-state taxonomy. Most carve-out states issue separate PA criteria and separate forms per indication (New York, Ohio, Kentucky, and Oklahoma each maintain distinct PA criteria documents for Wegovy MACE, Wegovy MASH, and Zepbound OSA). Iowa consolidates all three into a single Incretin Mimetics for Non-Diabetes Indications PA Criteria document and a single Request for Prior Authorization form 470-0058 (rev 1/26).

PA Form 470-0058 Verbatim Header

(Verified via iowamedicaidpdl.com/content/dam/ffs-medicaid/ia/incretin-mimetics-non-diabetes-pa-npi-0126.pdf, PDF 121KB, 5 pages, 2026-05-10):

“Request for Prior Authorization
Incretin Mimetics for Non-Diabetes Indications
FAX Completed Form To 1 (800) 574-2515
Provider Help Desk 1 (877) 776-1567
(PLEASE PRINT – ACCURACY IS IMPORTANT)

Prescriber must complete all information above. It must be legible, correct, and complete or form will be returned.”

PA Criteria: Full Verbatim Text (PA Criteria Chart Effective June 1, 2026, Pages 34–36)

(Verified via iowamedicaidpdl.com/content/dam/ffs-medicare/ia/pa-criteria-chart-effective-june-2026.pdf, PDF 824KB, 82 pages, 2026-05-10):

“Incretin Mimetics for Non-Diabetes Indications.

Prior authorization (PA) is required for incretin mimetics not otherwise covered by the Anti-Diabetics Non-Insulin Agents PA criteria for covered FDA approved or compendia indications. Payment for excluded medical use(s) (e.g. weight loss), as defined in the Iowa State Plan and Iowa Administrative Code 441 – 78.2(4) will be denied. Payment will be considered under the following conditions:

1. Request adheres to all FDA approved labeling for requested drug and indication, including dosing, contraindications, warnings and precautions, drug interactions, and use in specific populations; and
2. Patient has been screened for and does not have type 1 or type 2 diabetes mellitus; and
3. The requested drug will be used to reduce the risk of major adverse cardiovascular events (MACE) (cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke) in an adult with established cardiovascular disease (CVD) and either obesity or overweight; and
 a. Patient has established CVD, i.e. coronary artery disease (angina, MI), cerebrovascular disease (stroke, transient ischemic attack), peripheral arterial disease, heart failure, atrial fibrillation and other arrhythmias, valvular heart disease, congenital heart disease, cardiomyopathies, aortic disease (aneurysm, dissection), DVT or PE, and
 b. Patient has a baseline body mass index (BMI) ≥ 27 kg/m², obtained within 6 months of request; and
 c. Patient has been evaluated for cardiovascular standard of care treatment; and
 d. For Wegovy:
  i. Patient is ≥ 18 years of age; and
  ii. Initiation and escalation dosages will be permitted for a maximum of 8 weeks for each dosage; and
  iii. Maintenance dosages other than 1.7 mg or 2.4 mg once weekly will not be approved for maintenance treatment; or
4. Patient has a diagnosis of moderate to severe obstructive sleep apnea (OSA); and
 a. Patient has a baseline BMI ≥ 30 kg/m²; and
 b. Prescriber attests patient has a recent (within prior three years) apnea/hypopnea index (AHI) ≥ 15 events per hour, as documented by a polysomnography (PSG) or at-home sleep study (document AHI); and
 c. For Zepbound:
  i. Patient meets the FDA approved age for OSA; and
  ii. Initiation and escalation dosages will be permitted up to a maximum of 20 weeks prior to reaching the recommended maintenance dosage of 10 mg to 15 mg once weekly; and
  iii. Maintenance dosages other than 10 mg to 15 mg once weekly will not be approved for maintenance treatment; or
5. Patient has a diagnosis of noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH); and
 a. Patient has moderate to advanced liver fibrosis (stages F2 to F3 fibrosis) as confirmed by one of the following (attach results from testing documenting fibrosis stage);
  i. Liver stiffness measurement (LSM) by vibration-controlled transient elastography (VCTE) (e.g. FibroScan), with a LSM of 8 kPa to 15 kPa; or
  ii. LSM by magnetic resonance elastography (MRE) with a LSM of 3.1 kPa to 4.4 kPa; or
  iii. Liver biopsy with a non-alcoholic fatty liver disease (NAFLD) Activity Score (NAS) ≥ 4 with a score of 1 or more in steatosis, lobular inflammation, and hepatocyte ballooning; and
 b. Patient has been evaluated for cardiometabolic standard of care treatment; and
 c. Concurrent use of an incretin mimetic with resmetirom (Rezdiffra) for the treatment of MASH will only be considered after documented trials of each agent individually at therapeutic doses, with evidence of inadequate response; and
 d. Patient has not had significant alcohol consumption within the past year (> 20 g per day in women or > 30 g per day in men); and
 e. For Wegovy:
  i. Initiation and escalation dosages will be permitted for a maximum of 8 weeks for each dosage; and
  ii. Maintenance dosages other than 1.7 mg or 2.4 mg once weekly will not be approved for maintenance treatment; and
6. Patient will use medication in combination with a reduced calorie diet and increased physical activity; and
7. The requested agent will not be used in combination with other incretin mimetics.”

Continuation-of-Therapy Criteria (Page 36)

“Requests will be considered for initiation and appropriate dose escalation. Requests for continuation of therapy, once at an established maintenance dose will be considered at 12-month intervals, when:

1. The requested drug will be used to reduce the risk of MACE; and
 a. Patient has been evaluated for cardiovascular standard of care treatment; and
 b. For Wegovy, a maintenance dose of 1.7 mg or 2.4 mg once weekly is requested; and
2. The requested drug will be used to treat moderate to severe OSA; and
 a. Documentation of a positive response to therapy is provided; and
 b. The maintenance dose is requested and maintained (Zepbound 10 mg to 15 mg once weekly); and
3. The requested drug will be used for noncirrhotic MASH; and
 a. Documentation of a positive response to therapy (e.g., improvement in or stabilization of fibrosis, improvement in liver function such as reduction in alanine aminotransferase [ALT], improvement in LSM by VCTE, MRE, or biopsy); and
 b. Patient has not progressed to cirrhosis; and
 c. For Wegovy, a maintenance dose of 2.4 mg once weekly is requested, or 1.7 mg weekly with documentation of an adequate trial and intolerance to the maintenance dose of 2.4 mg once weekly. Patient must have a retrial of the recommended maintenance dose of 2.4 mg once weekly at least annually before a maintenance dose of 1.7 mg will be reauthorized; and
4. Patient does not have type 1 or type 2 diabetes; and
5. Patient continues to use medication in combination with a reduced calorie diet and increased physical activity; and
6. The requested agent will not be used in combination with other incretin mimetics.”

Key operational notes on the unified PA structure:

• Annual re-authorization (12-month interval) is more permissive than New York’s 6-month re-authorization and Wisconsin’s 6-month-with-5%-weight-loss requirement.
• The diabetes screen is a hard binary requirement— “Patient has been screened for and does not have type 1 or type 2 diabetes mellitus” — meaning T2DM patients with CVD, OSA, or MASH are routed through the Anti-Diabetics PA pathway (for Mounjaro/Ozempic for T2DM), not this pathway.
• The Wegovy MASH 2.4 mg annual retrial requirementis operationally distinctive — a patient maintained on 1.7 mg must annually retry 2.4 mg before 1.7 mg can be re-approved for MASH.
• Form 470-0058 footer: “470-0058 (1/26)” — the most recent revision is January 2026. Verify current version at iowamedicaidpdl.com/pa-pdl/pa-forms.html before submission.

Wegovy MACE: More Permissive Than Oklahoma’s Criteria

Iowa’s Wegovy MACE carve-out is a counter-intuitive finding — Iowa is generally categorized as a conservative Medicaid state, but its MACE criteria are operationally more permissive than Oklahoma’s (Pattern #24), which holds the title of most carve-out indications in the cluster.

The comparison, based on the respective PA criteria documents:

Iowa’s MACE pathway is also more permissive than New York’s (Pattern #3), which requires BMI ≥ 40 and has a documented 2-lifetime-attempts cap. Oklahoma (Pattern #24) is the closest structural analog — same categorical exclusion + triple-carve-out architecture — but Iowa’s MACE pathway reaches substantially younger patients (18+ vs. 45+) and requires less documentation.

The Iowa PDL Drug Review for Wegovy dated 06/24/2024 (PDF 195KB, iowamedicaidpdl.com/content/dam/ffs-medicare/ia/Wegovy.pdf, verified 2026-05-10) reflects the P&T Committee’s prior-cycle assessment:

“PDL DRUG REVIEW
Proprietary Name: Wegovy®
Common Name: semaglutide injection
PDL Category: Endocrine and Metabolic Agents

Summary: Wegovy® has been shown to improve MACE outcomes in overweight and obese patients with co-existing cardiovascular risk factors, when added on to background treatment/risk-reduction therapy and combined with diet and exercise. It is recommended Wegovy® remains non-preferred to assure appropriate clinical parameters for use.

PDL Placement: Preferred
       Non-Preferred with Conditions (covered diagnosis only)

Prepared By: Iowa Medicaid    Date: 06/24/2024”

The 06/24/2024 review recommended Non-Preferred with Conditions; the June 1, 2026 PDL elevated Wegovy to Preferred with comment-code 12 — a PDL-status-elevation event occurring between the 2024 and 2026 PDL cycles. The covered-diagnosis-only logic is preserved at the comment-12 level rather than as a PDL-status condition.

Zepbound OSA: Clinical Criteria and Titration Window

The Zepbound OSA pathway under PA form 470-0058 maps to Zepbound’s December 2024 FDA approval for moderate-to-severe OSA in adults with obesity. Iowa’s OSA criteria are:

• BMI ≥ 30 kg/m² — at or above the obesity threshold (same as Oklahoma, Alabama, and Louisiana OSA pathways)
• AHI ≥ 15 events per hour documented by polysomnography (PSG) or at-home sleep study (HSAT) within the prior 3 years — prescriber must attest and document the AHI value
• FDA-approved age for OSA — as of May 2026, the FDA-approved population is adults; no pediatric OSA indication exists for Zepbound
• No T1DM/T2DM — the binary diabetes screen (criterion 2) applies to all three indication pathways

Titration parameters for Zepbound under the Iowa OSA pathway:

• Initiation and escalation permitted up to a maximum of 20 weeks prior to reaching the recommended maintenance dosage (longer than Wegovy’s 8-weeks-per-step constraint)
• Maintenance dosage: 10 mg to 15 mg once weekly only— lower doses (2.5 mg, 5 mg, 7.5 mg) are titration steps, not approved maintenance
• Continuation-of-therapy requires “documentation of a positive response to therapy” and maintenance of the 10–15 mg weekly maintenance dose

The PDL Drug Review for Zepbound dated 02/14/2025 (PDF, verified via iowamedicaidpdl.com/content/dam/ffs-medicare/ia/drug-monographs/ndr-zepbound-02142025.pdf, 2026-05-10) notes the OSA clinical context:

“Place in Therapy: Zepbound® is a glucose-dependent insulinotropic polypeptide (GIP) receptor and glucagon-like peptide-1 (GLP-1) receptor agonist indicated in combination with a reduced-calorie diet and increased physical activity to: reduce excess body weight and maintain weight reduction long term in adults with obesity or adults with overweight in the presence of at least one weight-related comorbid condition, as well as to treat moderate to severe obstructive sleep apnea (OSA) in adults with obesity. A limitation of use includes that coadministration with other tirzepatide-containing products or with any GLP-1 receptor agonist is not recommended. The backbone of treatment for adults with OSA and an AHI ≥15 events per hour of sleep is positive airway pressure (PAP) therapy.”

The reference to PAP therapy as the “backbone of treatment” is a framing element — Iowa’s Zepbound OSA carve-out is positioned as adjunctive to PAP, consistent with the FDA labeling. The PA criteria do not explicitly require documented PAP failure (unlike Oregon’s OSA criteria, which require PAP-failure documentation). The AHI ≥ 15 documentation requirement and the BMI ≥ 30 floor are the operative clinical gates.

The 02/14/2025 review recommended Non-Preferred with Conditions to “confirm the appropriate diagnosis and clinical parameters for use”; the June 1, 2026 PDL elevated Zepbound to Preferred with comment-12 — same PDL-status-elevation trajectory as Wegovy.

Wegovy MASH: Adopted Within ~5 Months of FDA Approval

Wegovy received FDA accelerated approval for noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH) on August 15, 2025. By January 2026 — approximately 5 months later — Iowa Medicaid had:

• Updated the Incretin Mimetics for Non-Diabetes Indications PA Criteria to include the MASH carve-out with full fibrosis-staging requirements
• Updated Request for Prior Authorization form 470-0058 (rev 1/26) with MASH-specific attestation fields
• Maintained the carve-out as a Preferred-with-comment-12 entry on the June 1, 2026 PDL under the same Endocrine Metabolic Agents class as the MACE carve-out

This adoption speed is faster than several positive-coverage peers (states that already covered GLP-1s for obesity and needed to add MASH as a separate carve-out) and faster than Alabama (Pattern #23), which has not yet adopted the MASH indication as of May 10, 2026.

The MASH carve-out clinical requirements are the most documentation-intensive of the three pathways:

• Fibrosis stage F2 or F3 confirmed by one of: FibroScan VCTE 8–15 kPa, MRE 3.1–4.4 kPa, or liver biopsy with NAS ≥ 4 (score of 1+ in steatosis, lobular inflammation, and hepatocyte ballooning). Attach test results.
• No T1DM/T2DM (binary diabetes screen required)
• No cirrhosis — the carve-out is for noncirrhotic MASH; progression to cirrhosis at continuation disqualifies the patient
• No significant alcohol consumption within the past year (> 20 g/day women or > 30 g/day men) — abstinence or low-level consumption required
• Cardiometabolic standard of care evaluated before requesting Wegovy
• Sequential trial required if using Rezdiffra (resmetirom) — concurrent use of Wegovy + Rezdiffra is “only considered after documented trials of each agent individually at therapeutic doses, with evidence of inadequate response”
• Maintenance dose: 1.7 mg or 2.4 mg once weekly only

The annual retrial requirement at continuation is unique to the MASH pathway: a patient on 1.7 mg weekly must annually retry 2.4 mg before 1.7 mg is re-approved — “Patient must have a retrial of the recommended maintenance dose of 2.4 mg once weekly at least annually before a maintenance dose of 1.7 mg will be reauthorized.” This prevents indefinite low-dose maintenance without demonstrated intolerance to the higher dose.

Iowa’s MASH adoption gives it more carve-out breadth than Alabama (2 carve-outs: OSA + MACE, no MASH) and the same three-indication scope as Oklahoma (3 non-Imcivree carve-outs: MACE + MASH + OSA), Kentucky, and the post-Phase-2 Washington Apple Health (MACE + MASH + OSA).

PBM = Optum (UnitedHealth Group Subsidiary): UHC Exited as MCO in 2019 But Optum Retained the State PBM Contract

The PBM contractor for Iowa Medicaid pharmacy benefits is Optum, a UnitedHealth Group (UHG) subsidiary. This is confirmed by the public-facing infrastructure of the Iowa Medicaid PDL portal (iowamedicaidpdl.com), which is operationally hosted on UHG infrastructure:

• Content-security-policy headers referencing *.uhg.com, *.optum.com, *.uhc.com, *.pagescdn.com domains
• PDL inquiry email: pba_iapdlinfo@optum.com
• Rebate inquiry email: Iowa_Rebate@optum.com
• Iowa HHS policy contact: abby.cate@hhs.iowa.gov

The structural distinction that matters: UnitedHealthcare exited Iowa Health Link as a managed care organization (MCO) in 2019 following financial losses. But Optum — a separate UHG subsidiary operating at the state PBM-contract level (PDL, PA queue, rebate negotiations) — retained that state contract. UHG’s commercial relationship with Iowa Medicaid persists at the PBM-vendor level even after the MCO-exit.

This is the cleanest illustration in the 31-state series of how a vendor can be carved out from one role (MCO delivering medical benefits) and retained in another (state PBM contractor operating the PDL and PA queue). The two roles are structurally distinct:

• Optum’s PBM role: Operates the PDL portal (iowamedicaidpdl.com), administers the PA queue (fax 1-800-574-2515, Provider Help Desk 1-877-776-1567), manages rebate negotiations with manufacturers, and maintains the PA Criteria Chart. Optum serves in this role for the Iowa Medicaid program as a whole — FFS, MCO pharmacy deferral, and IHAWP.
• What UHC’s MCO role was (2016–2019): UnitedHealthcare Plan of the River Valley was one of three original Iowa Health Link MCOs when the program launched April 1, 2016. UHC administered medical benefits (physician services, hospital, behavioral health) for its enrolled Iowa Health Link members. UHC exited in 2019.

Prescribers and members who search for Iowa Medicaid pharmacy questions should direct PA submissions and PA status checks through the Optum-administered Provider Help Desk at 1-877-776-1567, not UnitedHealthcare or UHC member services (UHC has no current Iowa Health Link role).

The Three Iowa Health Link MCOs and PDL Deferral Architecture

Iowa Health Link — the statewide managed care program launched April 1, 2016 — currently operates with three MCOs (verified via Iowa HHS Iowa Health Link Member Resources page, 2026-05-10):

“Iowa Total Care: 1-833-404-1061
Molina Healthcare of Iowa: 1-844-236-0894
Wellpoint Iowa: 1-833-731-2140
Iowa HHS member services: (800) 972-2017”

Current MCO contract identifiers (verified via Iowa HHS Medicaid Contracts & Rates page, 2026-05-10):

• Iowa Total Care — Contract MEDIOMC26002 (3 amendments)
• Molina Healthcare of Iowa — Contract MED 24-005 (11 amendments)
• Wellpoint Iowa — Contract MED 24-006 (12 amendments)

All three MCOs defer to the state Iowa Medicaid PDL for pharmacy benefits. Verbatim from each MCO:

Iowa Total Care (verified via iowatotalcare.com/members/medicaid/benefits-services/pharmacy.html, 2026-05-10):

“Iowa Total Care uses the state’s Preferred Drug List (PDL), not a separately administered formulary.”

Molina Healthcare of Iowa (verified via molinahealthcare.com/providers/ia/medicaid/resources/pharmacy.aspx, 2026-05-10):

“Molina Healthcare covers all medications listed on the Iowa Medicaid Preferred Drug List (PDL). Pharmacy benefit coverage is aligned with the Iowa Medicaid Preferred Drug List available at iowamedicaidpdl.com.”

Wellpoint Iowa (formerly Amerigroup Iowa, an Anthem/Elevance Health subsidiary; verified via provider.wellpoint.com pharmacy information page, 2026-05-10):

“Wellpoint has a list of preferred drugs chosen for quality and effectiveness for Iowa members, called a Preferred Drug List (PDL). Wellpoint works with CarelonRx to provide these benefits.”

Wellpoint Iowa’s reference to CarelonRx (the Anthem/Elevance subsidiary PBM) is a general statement of how Wellpoint administers commercial pharmacy benefits. For Iowa Health Link members, the operational PDL is the state’s. The CarelonRx infrastructure does not override the Iowa Medicaid statewide PDL.

The practical implication: there is no MCO-specific formulary that diverges from the state PDL for Wegovy or Zepbound. A prescriber who calls Iowa Total Care, Wellpoint, or Molina member services about Wegovy chronic-weight-management coverage will receive the same comment-12 / non-coverage answer as a FFS member. PA questions should be directed to the Iowa Medicaid Provider Help Desk at 1-877-776-1567.

Iowa Health Link MCO Churn History: 2 of 3 Original MCOs Exited Within 3 Years

Iowa Health Link’s MCO roster has turned over substantially since launch — a structural feature that is distinctive in the 31-state taxonomy and is relevant context for prescribers and members using pre-2019 Iowa Medicaid references.

Iowa Health Link launched April 1, 2016 under federal CMS approval (letter dated February 23, 2016) with three original MCOs:

• Amerigroup Iowa, Inc. (Anthem/Elevance Health subsidiary) — one of the three original 2016 contractors; subsequently rebranded as Wellpoint Iowa, Inc. following Anthem’s broader corporate rebranding. Wellpoint is the only original 2016 MCO still in the program.
• AmeriHealth Caritas Iowa, Inc. — exited the Iowa market in 2017 due to financial losses. First original MCO to exit.
• UnitedHealthcare Plan of the River Valley, Inc. — exited in 2019. Second original MCO to exit. UHC’s state PBM relationship (Optum) has persisted throughout.

The replacements entering after AmeriHealth Caritas’ 2017 and UHC’s 2019 exits:

• Iowa Total Care (Centene Corporation) — entered the program in 2019 following UnitedHealthcare’s exit. Current contract MEDIOMC26002.
• Molina Healthcare of Iowa — entered subsequently following AmeriHealth Caritas’ 2017 exit. Current contract MED 24-005.

2 of 3 original MCOs exited within 3 years of launch— an MCO churn rate that is structurally distinctive in the 31-state taxonomy. Most state Medicaid managed care programs have more stable MCO rosters over 3-year windows. Prescribers and members who have pre-2019 Iowa Health Link coverage materials should verify current MCO enrollment at Iowa HHS (hhs.iowa.gov/programs/welcome-iowa-medicaid/iowa-health-link).

Iowa Health and Wellness Plan (IHAWP): Structural Coverage Parity with FFS Medicaid

The Iowa Health and Wellness Plan (IHAWP) is Iowa’s Section 1115 demonstration-waiver-based Medicaid expansion program. Key verified facts (medicaid.gov Iowa Wellness Plan listing, project #11-W-00289; Iowa HHS IHAWP page, both verified 2026-05-10):

• CMS approval date: December 10, 2013
• Iowa Legislature enactment date: May 23, 2013
• Implementation date: January 1, 2014
• Demonstration project #: 11-W-00289
• Population: Adults ages 19–64 with household incomes not exceeding 133% of the Federal Poverty Level

The IHAWP eligibility description (verified via Iowa HHS IHAWP page, 2026-05-10):

“The Iowa Health and Wellness Plan (IHAWP) provides health coverage at low or no cost to Iowans between the ages of 19 and 64. Eligibility is based on household income.”

Eligibility criteria (effective April 1, 2026):
“— Age 19–64
— Income not exceeding 133% of Federal Poverty Level (effective April 1, 2026)
— Iowa residence and U.S. citizenship
— Not otherwise eligible for Medicaid or Medicare”

Critical parity finding: IHAWP operates under the same statewide Iowa Medicaid PDL and the same Incretin Mimetics for Non-Diabetes Indications PA criteria as Iowa Medicaid Fee-for-Service. There is no separate IHAWP formulary, no separate PA criteria, and no separate weight-management benefit. The Iowa HHS IHAWP benefits page lists prescription drugs as a covered benefit — under the same statewide PDL structure:

“Membership in the Iowa Health and Wellness Plan includes many benefits such as the ones outlined below: Doctor visits, Women’s health visits, Prescription drugs, Preventive health services (e.g., vaccinations, blood pressure checks, and cancer screenings), Hospitalizations, Dental care, Emergency service, Mental health care, Substance use disorder treatment.”

What this means operationally:

• An IHAWP member with established CVD and BMI ≥ 27 (no T2DM) can submit form 470-0058 for Wegovy MACE — same criteria as a traditional FFS member.
• An IHAWP member who presents Wegovy or Zepbound for chronic weight management will receive a comment-12 / weight-loss-indication-not-covered denial — same outcome as a traditional FFS member.
• The IAC 441-78.2(4)(b)(2) categorical exclusion applies uniformly to IHAWP members.

This is structurally distinctive compared to states like New Jersey, where the NJ FamilyCare expansion population operates under separate MCO formularies that may diverge from the FFS PDL. Iowa’s expansion population has no parallel benefit-design divergence. Coverage parity between IHAWP and traditional FFS is structurally complete.

SF 552 / HF 701: Review-Only Mandate, Not a Coverage Mandate

The 2025–2026 Iowa legislative session produced one relevant GLP-1-adjacent bill: Senate File 552 (companion House File 701; successor to Senate Study Bill 1138), introduced March 6, 2025 by the Senate Committee on Health and Human Services with floor manager Sen. Mike Klimesh (R-District 32).

Verbatim SF 552 title (verified via legis.iowa.gov/docs/publications/LGI/91/SF552.pdf, PDF 36KB, LSB 1939SV (2) 91, 2026-05-10):

“Senate File 552 — Introduced
SENATE FILE 552
BY COMMITTEE ON HEALTH AND HUMAN SERVICES
(SUCCESSOR TO SSB 1138)

A BILL FOR
An Act relating to a review of anti-obesity medications by the department of health and human services and the department of administrative services for purposes of the medical assistance program and health insurance plans for state employees.”

Verbatim Section 1 — the operative mandate (same bill PDF):

“Section 1. ANTI-OBESITY MEDICATION REVIEW AND REPORT. For purposes of the medical assistance program under chapter 249A and health insurance plans for state employees established pursuant to chapter 509A, the department of health and human services and the department of administrative services shall review anti-obesity medications, including GLP-1 agonists, for effectiveness relating to weight loss, the impact on comorbidities, the potential for cost savings due to deferred medical procedures and reduced medications related to comorbidity, recommended eligibility requirements, any short-term and long-term costs associated with coverage, and any other criteria the departments deem relevant. The department of health and human services and the department of administrative services shall submit a report to the general assembly by January 5, 2026, with the departments’ findings, proposed eligibility requirements, and any short-term and long-term costs associated with coverage.”

Verbatim SF 552 legislative status (verified via FastDemocracy bill tracking, fastdemocracy.com/bill-search/ia/2025-2026/bills/IAB00021824/, 2026-05-10):

“Bill Status: Pending (Introduced)
Current Status: ‘Referred to Health and Human Services’ (Jun 16, 2025)
Introduction Date: Mar 06, 2025
Voting records: None”

What SF 552 is NOT:

• It does NOT amend IAC 441-78.2(4)(b)(2) — the categorical weight-loss drug exclusion remains fully in force.
• It does NOT alter the Iowa State Plan.
• It does NOT direct any specific coverage outcome.
• It does NOT mandate that Iowa Medicaid cover GLP-1s for obesity.

The HHS+DAS January 5, 2026 report: SF 552 required Iowa HHS and DAS to submit a report to the General Assembly by January 5, 2026. As of May 10, 2026 — four months past the statutory deadline — this report has not been verified as a publicly-published primary-source document. Searches of hhs.iowa.gov and the Iowa Legislature publications archive did not surface a finalized report. This item is marked [NOT VERIFIED] per the verifier brief; readers should contact the Iowa Legislative Services Agency (legservices@legis.iowa.gov) or Iowa HHS directly to request the report.

Comparison to analogous state legislation: Iowa’s SF 552 is an information-gathering posture — structurally weaker than New Jersey’s A3369, Maryland’s SB 0496/HB 0813, or Tennessee’s Public Chapter 530, all of which directly addressed Medicaid coverage of anti-obesity medications. Iowa’s legislative engagement is also structurally weaker than Kentucky’s (Pattern #21), which saw Gov. Beshear attempt an executive amendment that the legislature overrode via SB 65 on April 14, 2026 — a full legislative-reversal cycle that Iowa has not experienced. SF 552 has been at “Referred to Health and Human Services” for approximately 11 months without advancement as of May 10, 2026.

No 2026 Iowa bill has been identified that would directly amend IAC 441-78.2(4)(b)(2) or alter GLP-1 coverage in Iowa Medicaid. The 2026 Iowa legislative session’s primary Medicaid fiscal activity was an HMO premium tax increase bill (Iowa House, March 19, 2026) — fiscal/budget legislation with no GLP-1 coverage dimension.

Appeals: Iowa DIAL (Department of Inspections, Appeals and Licensing) Fair Hearings

Iowa Medicaid appeals for pharmacy PA denials run through a two-body structure (verified via Iowa HHS How to Appeal page and Iowa DIAL Administrative Hearings Division page, both 2026-05-10):

“A state fair hearing request is filed with HHS Appeals. If all hearing requirements are met, the appeal file is forwarded to the Department of Inspections, Appeals and Licensing so an appeal hearing can be scheduled.”

Filing deadlines (verbatim from Iowa HHS Appeals page):

“The timeframe for filing a Medicaid appeal depends on the type of action:
— Within 90 calendar days of the written notice for SNAP and Medicaid eligibility or fee for service actions
— Within 120 calendar days for managed care organization or dental carrier actions”

For GLP-1 PA denials specifically: A Wegovy or Zepbound PA denial is adjudicated centrally by the state Optum-administered PA queue, not by the MCO. This is a pharmacy / FFS PA denial — the 90-day state fair hearing window applies, not the 120-day MCO window. File within 90 calendar days of the written denial notice date.

The DIAL hearing structure (verbatim from Iowa HHS Appeals page):

“If you are eligible for a hearing, your appeal file will be sent to the Administrative Hearings Division of the Iowa Department of Inspections, Appeals and Licensing. They will schedule a telephone hearing and send you a written notice of the date and time. DIAL’s Administrative Hearings Division provides independent administrative law judges to make decisions regarding disputes primarily between private citizens and government agencies.”

The MCO pre-step for managed care benefit denials:

“When someone disagrees with an action taken by a managed care organization, federal regulations allow members, providers or authorized representatives to file an appeal. If a provider or authorized representative files an appeal, the Medicaid member must have given their express written consent before the appeal can proceed to a state fair hearing.”

DIAL Administrative Hearings Division: dial.iowa.gov/hearings/admin-hearings.

Important limitation on appeals for chronic-weight-management denials: A Wegovy or Zepbound denial for chronic weight management cannot be overturned on appeal — the IAC 441-78.2(4)(b)(2) categorical exclusion is binding. An appeal hearing cannot override a statutory or regulatory exclusion. The strongest appeal posture for Iowa Medicaid GLP-1 denials involves MACE/OSA/MASH patients who had documentation deficiencies in the PA form (missing diagnosis code, incomplete clinical attestation, outdated AHI study) that could be corrected on resubmission. See our GLP-1 insurance appeal playbook for the full appeal workflow including Iowa-specific DIAL procedures.

How Iowa Compares: OK / AL / KY Analogues + MO / WI / MN Inverse Midwest Peers

Iowa (Pattern #32) is positioned at the intersection of the categorical-exclusion carve-out cluster and the Midwest geographic cluster, making it comparable to both structural analogues and regional peers.

Oklahoma (Pattern #24) — Closest Structural Analogue: Both states have categorical regulatory exclusions (OK at OAC 317:30-5-72.1(1)(D); Iowa at IAC 441-78.2(4)(b)(2)); both have FDA-label-restricted carve-outs for MACE, MASH, and OSA; both are KFF-classified non-covering states; both operate MCO-defer-to-state-PDL architectures. Key differences: Oklahoma has 4 carve-outs (CV + MASH + OSA + Imcivree monogenic-obesity, unique in cluster); Iowa has 3 (CV + MASH + OSA, no Imcivree). Oklahoma uses 3 separate DUR-board-approved PA criteria documents; Iowa uses 1 unified PA form 470-0058. Oklahoma uses OU/PMC university-administered infrastructure; Iowa uses Optum-administered PBM. Iowa is MORE permissive on Wegovy MACE (age ≥ 18 vs. ≥ 45; broader CVD list; no A1C requirement). Iowa and Oklahoma are the cleanest paired examples of the carve-out-state architecture in the 31-state taxonomy — same posture, different operational implementation.

Alabama (Pattern #23) — Second-Closest Analogue: Both states have categorical regulatory exclusions; both are KFF-classified non-covering states; both have Wegovy MACE and Zepbound OSA carve-outs. Iowa has MORE carve-outs than Alabama (3 vs. 2 — Iowa adopted Wegovy MASH, Alabama has not). Alabama operationalizes Zepbound OSA via a PDL footnote; Iowa operationalizes it via the unified PA criteria + comment-12. Alabama’s Wegovy MACE criteria use a separate PA form (Form 369 Cardiac Agents section); Iowa uses the unified form 470-0058 for all three.

Kentucky (Pattern #21) — Third-Closest Analogue: Both states have categorical regulatory exclusions (KY at 907 KAR 23:010 Section 5(2)(a); Iowa at IAC 441-78.2(4)(b)(2)); both have Wegovy MACE/MASH and Zepbound OSA carve-outs; both are KFF-classified non-covering states. Key difference: Kentucky experienced an active legislative reversal cycle in 2025–2026 (Beshear amendment proposed → SB 65 veto → SB 65 override April 14, 2026); Iowa’s SF 552 is review-only, has not advanced beyond committee referral, and involves no executive-branch rulemaking initiative.

Missouri (Pattern #22) — Inverse Midwest Peer: Missouri is a positive-coverage state with Foundayo + Zepbound + Zepbound KwikPen on a dedicated Anti-Obesity PDL class; Iowa is a non-coverage-with-carve-outs state. Both are KFF-classified states (MO covering; Iowa non-covering). Both have unified statewide PDLs with state PBM contractors (MO via Conduent + Gainwell dual-vendor; Iowa via Optum). Missouri and Iowa are structurally opposite Midwest peers — MO’s affirmative coverage decision is what Iowa has not made. With Iowa shipping as Pattern #32, the Midwest coverage divide is now fully documented: MO (positive) vs. Iowa (non-covering carve-out); MN (positive) vs. WI (positive with restrictions) vs. Iowa (non-covering carve-out).

Wisconsin (Pattern #19) and Minnesota (Pattern #20) — Additional Midwest Peers: WI has affirmative coverage with a 2-lifetime-attempts cap and BMI < 24 renewal-revocation; MN has affirmative coverage with a dedicated Weight Management Agents PDL class. Both are positive-coverage states. Iowa is non-coverage with carve-outs — the most restrictive of the four Midwest states documented in the 31-state series.

What Iowa Medicaid Patients Can Do in 2026

Iowa Medicaid does not cover GLP-1s for chronic weight management. Within that constraint, here is the verified action framework:

If You Have Established Cardiovascular Disease (Wegovy MACE Pathway)

Ask your prescriber to complete form 470-0058 (fax to 1-800-574-2515). The clinical requirements are: age ≥ 18, established CVD (any of: coronary artery disease, stroke/TIA history, peripheral arterial disease, heart failure, atrial fibrillation, valvular heart disease, congenital heart disease, cardiomyopathies, aortic disease, DVT, PE), BMI ≥ 27 kg/m² documented within 6 months, no T1DM/T2DM, evaluated for cardiovascular standard of care. Iowa’s age threshold (18+) is more permissive than Oklahoma’s (45+) — younger adults with established CVD who would be denied in Oklahoma may qualify in Iowa.

If You Have Moderate-to-Severe OSA (Zepbound OSA Pathway)

Ask your prescriber to complete form 470-0058. Clinical requirements: BMI ≥ 30 kg/m², AHI ≥ 15 events/hour documented by polysomnography or at-home sleep study within the prior 3 years, no T1DM/T2DM. The prescriber must attest and document the specific AHI value on the form. Existing sleep studies within the 3-year window are acceptable — a new sleep study is not required if a qualifying recent study exists.

If You Have Noncirrhotic MASH (Wegovy MASH Pathway)

The MASH pathway requires the most documentation: FibroScan VCTE 8–15 kPa, MRE 3.1–4.4 kPa, or liver biopsy with NAS ≥ 4. A liver specialist (hepatologist or gastroenterologist) will typically be involved in the fibrosis staging. Attach the fibrosis test results to form 470-0058. No T1DM/T2DM, no cirrhosis, no significant alcohol consumption in the past year.

If You Only Have Obesity (No CVD / OSA / MASH)

Iowa Medicaid has no pathway for Wegovy or Zepbound for chronic weight management without one of the three carve-out indications. Options in this scenario:

• NovoCare self-pay program: Wegovy available at $299/month for eligible uninsured or underinsured patients at NovoCare.com. Income-based eligibility applies.
• LillyDirect self-pay program: Zepbound available at $399–$549/month (by vial) for self-pay patients at LillyDirect.com/zepbound.
• Foundayo (oral orforglipron): Not listed on the Iowa Medicaid PDL. No coverage pathway exists. If approved for weight management by FDA and listed on a future PDL cycle, the same comment-12 / weight-loss-exclusion logic would apply unless IAC 441-78.2(4)(b)(2) is amended.
• Contact Iowa HHS / legislative representatives: SF 552 / HF 701 (review-and-report mandate, pending since June 2025) is the current legislative vehicle. Contacting Sen. Klimesh (SD-32, floor manager) or the Senate Health and Human Services Committee may support advancement of the bill.

If You Are an IHAWP Member

The same rules apply. IHAWP operates under the same statewide PDL and PA criteria. Your MCO member services line (Iowa Total Care 1-833-404-1061, Wellpoint Iowa 1-833-731-2140, Molina 1-844-236-0894) can confirm enrollment, but PA decisions for pharmacy benefits are governed by the state PDL and adjudicated centrally. PA questions go to Provider Help Desk: 1-877-776-1567.

Primary Sources

All sources verified 2026-05-10 via direct curl + pdftotext extraction or WebFetch.

1. Iowa Medicaid PDL effective June 1, 2026 — PDF 1.5MB, document control RT14773, generated 4/24/2026; iowamedicaidpdl.com/content/dam/ffs-medicaid/ia/ia-pdl-effective-06012026.pdf
2. PA Criteria Chart effective June 1, 2026 — PDF 824KB, 82 pages, Incretin Mimetics for Non-Diabetes Indications at pp. 34–36; iowamedicaidpdl.com/content/dam/ffs-medicare/ia/pa-criteria-chart-effective-june-2026.pdf
3. IAC 441 Chapter 78 — PDF 329KB, 9,835 lines, effective IAC 10/15/25; legis.iowa.gov/docs/iac/chapter/441.78.pdf
4. Iowa Code Chapter 249A — PDF, Iowa Code 2026 edition, dated December 9, 2025; legis.iowa.gov/docs/code/249A.pdf
5. PA Form 470-0058 (rev 1/26) — PDF 121KB, 5 pages, Incretin Mimetics for Non-Diabetes Indications; iowamedicaidpdl.com/content/dam/ffs-medicaid/ia/incretin-mimetics-non-diabetes-pa-npi-0126.pdf
6. PDL Drug Review for Wegovy® dated 06/24/2024 — PDF 195KB, 6 pages; iowamedicaidpdl.com/content/dam/ffs-medicare/ia/Wegovy.pdf
7. PDL Drug Review for Zepbound® dated 02/14/2025 — PDF, 6 pages; iowamedicaidpdl.com/content/dam/ffs-medicare/ia/drug-monographs/ndr-zepbound-02142025.pdf
8. SF 552 (Senate File 552) — PDF 36KB, LSB 1939SV (2) 91; legis.iowa.gov/docs/publications/LGI/91/SF552.pdf
9. Iowa HHS Iowa Health Link Member Resources — hhs.iowa.gov/programs/welcome-iowa-medicaid/iowa-health-link/member-resources
10. Iowa HHS Iowa Health and Wellness Plan — hhs.iowa.gov/medicaid/plans-programs/iowa-health-wellness-plan
11. Iowa HHS Medicaid Contracts & Rates — hhs.iowa.gov/medicaid/about-medicaid/policies-rules-regulations/contracts-rates
12. Iowa Total Care Pharmacy Benefits — iowatotalcare.com/members/medicaid/benefits-services/pharmacy.html
13. Wellpoint Iowa Provider Pharmacy Information — provider.wellpoint.com/iowa-provider
14. Molina Healthcare of Iowa Pharmacy — molinahealthcare.com/providers/ia/medicaid/resources/pharmacy.aspx
15. Iowa HHS How to Appeal — hhs.iowa.gov/appeals/how-appeal
16. Iowa DIAL Administrative Hearings — dial.iowa.gov/hearings/admin-hearings
17. KFF January 2026 Medicaid GLP-1 tracker — kff.org/medicaid/medicaid-coverage-of-and-spending-on-glp-1s/
18. 42 U.S.C. § 1396r-8(d)(2) — federal optional-exclusion authority; law.cornell.edu/uscode/text/42/1396r-8
19. FastDemocracy SF 552 bill tracking — fastdemocracy.com/bill-search/ia/2025-2026/bills/IAB00021824/
20. Medicaid.gov Iowa Wellness Plan demonstration — project #11-W-00289